Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

By Zacks Investment ResearchStock MarketsNov 30, 2021 10:09PM ET
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
By Zacks Investment Research   |  Nov 30, 2021 10:09PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

AstraZeneca (NASDAQ:AZN) AZN and partner Merck MRK announced that the FDA has accepted their supplemental new drug application (sNDA) seeking expanded use of PARP inhibitor Lynparza in breast cancer.

The sNDA is seeking approval of Lynparza as an adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer previously treated with chemotherapy either before or after surgery.

With the FDA granting priority review to AstraZeneca and Merck’s sNDA, a decision is expected in the first quarter of 2022

The sNDA for the expanded indication was based on data from the OlympiA phase III study. In the study, treatment with Lynparza reduced the risk of invasive breast cancer recurrence, second cancers or death by 42% versus placebo, thereby demonstrating statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS).

Lynparza is already approved for the treatment of germline BRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial.

An estimated 2.3 million patients were diagnosed with breast cancer in 2020. Around 91% of all breast cancer patients are diagnosed at an early stage of the disease. If Lynparza is approved for the early breast cancer indication, it can cater to a significantly expanded patient population.

This year so far, AstraZeneca’s shares have risen 9.7% while Merck’s shares have lost 7.5%. The industry has witnessed an increase of 12.9% in the said time frame.

Zacks Investment Research
Zacks Investment Research
Image Source: Zacks Investment Research

At present, Lynparza, is approved for four cancer types, ovarian, breast, prostate and pancreatic for various patient populations. It has been used to treat over 40,000 patients worldwide. Lynparza is also being evaluated in an earlier-line setting for the approved cancer indications as well as some other cancer types.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck. The drug generated product sales of $1.72 for AstraZeneca in the first nine months of 2021, and alliance revenues of $721 million for Merck.

Other PARP inhibitors available in the market include Glaxo’s GSK Zejula and Clovis Oncology (NASDAQ:CLVS)’s CLVS Rubraca and Pfizer’s Talzenna.

While Glaxo’s Zejula is approved only for an ovarian cancer indication, Clovis’ Rubraca is approved for BRCA mutated ovarian cancer and metastatic castrate-resistant prostate cancer indications.

A broad development program on Rubraca is currently underway across a variety of solid tumors. Clovis is looking to expand Rubraca’s label into additional cancer types like breast and gastroesophageal cancers, among others.

On the other hand, Glaxo’s Zejula is being evaluated for additional ovarian cancer stages as well as for non-small cell lung cancer and breast cancer

Both Merck and AstraZeneca have a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in a little more than 9 months and Nvidia (NASDAQ:NVDA) which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

GlaxoSmithKline plc (NYSE:GSK): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

Related Articles

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email